Kintara Therapeutics

Kintara Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of new cancer therapies. Its product pipeline includes VAL-083 and REM-001. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

TuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, FL.

Kintara Therapeutics (NASDAQ:KTRA) Inc ended its fiscal first quarter with over $19.3 million in the bank to fund work on its novel cancer therapies. The cash figure was an increase over the previous quarter, when it finished with $10.5 million.

Kintara Therapeutics boosts cash position in fiscal 1Q to $19.3M as it works on novel cancer therapies

SAN DIEGO, Nov. 15, 2021 /PRNewswire/ -- https://www.kintara.com/ (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal first quarter ended September 30, 2021 and provided a corporate update. CORPORATE HIGHLIGHTS AND RECENT DEVELOPMENTS Positioned our management team for our next stage of development by announcing that Robert E.

Kintara Therapeutics Announces Fiscal 2022 First Quarter Financial Results and Provides Corporate Update

SAN DIEGO, Nov. 11, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announces today that its Chief Executive Officer, Robert E. Hoffman, will present a corporate overview at the Q4 Investor Summit Conference, which is being held virtually on November 16 – 17, 2021.

Kintara Therapeutics to Present at the Q4 Investor Summit Virtual Conference on November 17, 2021

Two Phase 3-ready therapeutics Well capitalized to achieve clinical milestones Multiple US/EU Orphan Drug and Fast Track designations What Kintara Therapeutics does: Kintara Therapeutics, Inc (NASDAQ:KTRA) is developing advanced cancer therapies for patients with rare unmet medical needs. The San Diego-based company is currently developing two Phase 3-ready therapeutics: VAL-083 for treating glioblastoma (GBM), the most common and most aggressive form of primary brain cancer in adults and; REM-001 for treating cutaneous metastatic breast cancer (CMBC).

Kintara Therapeutics is developing innovative cancer therapies for rare, unmet medical needs

Kintara Therapeutics (NASDAQ:KTRA) Inc has announced that its chairman, Robert Hoffman, has succeeded Saiid Zarrabian as the company's president and CEO effective November 8, 2021. Kintara said Hoffman will continue in his role as the company's chairman, while Zarrabian will transition to lead Kintara's strategic partnerships initiative and will remain a member of its board of directors.

Kintara Therapeutics appoints Robert Hoffman as its new CEO

SAN DIEGO, Nov. 9, 2021 /PRNewswire/ -- https://www.kintara.com/ (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that Robert E. Hoffman, the Company's Chairman, will succeed Saiid Zarrabian as President and Chief Executive Officer, effective November 8, 2021.

Kintara Announces Changes to Executive Leadership Team

Camber Energy

Meten Holding Group Ltd.

Are these penny stocks worth it at their current levels? The post Do These Penny Stocks Present a Buying Opportunity At Current Levels?

Do These Penny Stocks Present a Buying Opportunity At Current Levels?

Agile Therapeutics

Progenity

Sesen Bio Inc.

Looking for biotech penny stocks to watch on Reddit? Check these four out for your list The post Best Biotech Penny Stocks on Reddit to Buy Now?

Best Biotech Penny Stocks on Reddit to Buy Now? 4 For Your Watchlist

The stock price of Kintara Therapeutics Inc (NASDAQ: KTRA) increased by over 20% this past week. This is why it happened.

KTRA Stock: Why It Increased This Week

SAN DIEGO, Oct. 11, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announces today that its Chief Executive Officer, Saiid Zarrabian, will present a corporate overview at the 14th Annual LD Micro Main Event Conference which is being held at the Luxe Sunset Bel-Air in Los Angeles from October 12 – 14, 2021. Mr. Zarrabian will deliver his corporate presentation on October 12, 2021 at 2:00 p.m.

Kintara Therapeutics to Present at the LD Micro Main Event Conference

Kintara Therapeutics Inc, an oncology-focused, clinical-stage biopharmaceutical company received a ‘Buy' rating from Aegis Capital.  The analysts noted the biotech firm, which is developing VAL-083 for the treatment of glioblastoma multiforme (GBM) and REM-001 for the treatment of cutaneous metastatic breast cancer has several catalysts ahead that could lead to company growth.

Aegis Capital gives Kintara Therapeutics a ‘Buy' rating

Kintara Therapeutics(NASDAQ:KTRA) stock fell by 5.89% on Wednesday after the company reported its Q4 earnings results on Tuesday, September 28, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

Kintara Therapeutics: Q4 Earnings Insights

Kintara Inc, a biopharmaceutical company focused on the development of new solid tumor cancer therapies, reports that it closed its fiscal year on June 30 with cash and cash equivalents of about $10.5 million. In a statement, the company noted that its balance sheet as of September 28 grew even stronger as it closed on a registered direct offering, priced at-the-market under Nasdaq rules, raising about $15 million to help fund ongoing clinical studies and corporate working capital needs.

Kintara heads into new fiscal year with strengthened balance sheet

SAN DIEGO, Sept. 29, 2021 /PRNewswire/ -- https://www.kintara.com/ (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal year ended June 30, 2021 and provided a corporate update.

Kintara Therapeutics Announces Fiscal Year 2021 Financial Results and Provides Corporate Update

SAN DIEGO, Sept. 28, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company developing novel cancer therapies for patients who are failing, or are resistant to, current treatment regimens today announced the closing of its previously announced registered direct offering, priced at-the-market under Nasdaq rules, with several healthcare-focused institutional investors of 12,000,000 shares of its common stock (or common stock equivalents) and warrants to purchase up to an aggregate of 12,000,000 shares of common stock, at a combined offering price of $1.25 per share and associated warrant.

Kintara Announces Closing of $15.0 million Offering Priced at a Premium to Market

Kintara Therapeutics Inc has entered into securities purchase agreements with certain healthcare-focused institutional investors to raise about $15 million in gross proceeds.  The company said it intends to use the net proceeds to fund its clinical studies, working capital, and other general corporate purposes.

Kintara announces $15M common stock and warrants offering priced at premium to market

SAN DIEGO, Sept. 24, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company developing novel cancer therapies for patients who are failing, or are resistant to, current treatment regimens today announced that it has entered into securities purchase agreements with certain healthcare-focused institutional investors to raise approximately $15 million in gross proceeds, before placement agent fees and other offering expenses payable by Kintara, through the issuance of 12,000,000 shares of its common stock (or common stock equivalents) and investor warrants to purchase up to an aggregate of 12,000,000 shares of common stock in a registered direct offering priced at-the-market under Nasdaq rules.

Kintara Announces $15.0 million Offering of Common Stock and Warrants Priced at a Premium to Market

SAN DIEGO, Sept. 22, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company developing novel cancer therapies for patients who are failing, or are resistant to, current treatment regimens today announced topline data results from the newly-diagnosed adjuvant arm of its open-label, Phase 2 clinical study being conducted at the MD Anderson Cancer Center (MD Anderson) in Houston, Texas.

Kintara Reports Topline Results from Phase 2 Clinical Study of VAL-083 as Adjuvant Therapy for Newly-Diagnosed GBM Patients

Kintara Therapeutics Inc has announced that the VAL-083 treatment arm in the Global Coalition for Adaptive Research (GCAR) registrational Phase 2/3 clinical trial for glioblastoma multiforme (GBM) has now been activated in 26 US sites as of August 16, 2021. The GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment) trial is a patient-centered, adaptive platform trial for registration evaluating multiple therapies for patients with newly diagnosed and recurrent GBM.

Kintara Therapeutics says VAL-083 treatment arm in the Phase 2/3 clinical trial for glioblastoma multiforme now activated in 26 US sites

SAN DIEGO, Aug. 17, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that the VAL-083 treatment arm in the Global Coalition for Adaptive Research (GCAR) registrational Phase 2/3 clinical trial for glioblastoma multiforme (GBM) has been activated in 26 U.S. sites as of August 16, 2021. The trial, titled GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment), is a patient-centered, Phase 2/3 adaptive platform trial evaluating multiple therapies for patients with newly-diagnosed and recurrent GBM.

Kintara Therapeutics Provides Positive Site Activation Update on GCAR Phase 2/3 Clinical Trial for Glioblastoma

SAN DIEGO, Aug. 12, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA), a biopharmaceutical company developing novel cancer therapies for patients who are failing or are resistant to current treatment regimens, announced today that its Chief Executive Officer, Saiid Zarrabian, will present at the Investor Summit Conference being held August 17 – 18, 2021. Mr. Zarrabian will deliver his corporate presentation on August 17, 2021 at 12:30 p.m.ET.

Kintara Therapeutics to Present at the Investor Summit Virtual Conference on August 17, 2021

SAN DIEGO, Aug. 4, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA), a biopharmaceutical company developing novel cancer therapies for patients who are failing or are resistant to current treatment regimens, announced today that Saiid Zarrabian, Chief Executive Officer, will participate at the BTIG Virtual Biotechnology Conference on August 9, 2021. Mr. Zarrabian will deliver his corporate presentation on Monday, August 9, 2021 at 2:00 p.m.

Kintara Therapeutics to Present at the BTIG Virtual Biotechnology Conference on August 9, 2021

Kintara Therapeutics Inc (NASDAQ: KTRA) has announced topline data from Phase 2 study of its lead compound VAL-083, conducted at the MD Anderson Cancer Center. The Phase 2 trial is a two-arm, biomarker-driven study testing VAL-083 in glioblastoma multiforme patients who have an unmethylated promoter of the methylguanine DNA-methyltransferase gene.

Kintara Therapeutics Shows Encouraging Safety, Efficacy Data From Brain Cancer Study With VAL-083

Kintara Therapeutics Inc (NASDAQ:KTRA) (FRA:3DM) (OTCMKTS:DMPWW) has announced topline data results from the recurrent arm of its open-label, Phase 2 clinical study of its lead compound VAL-083 being conducted at the MD Anderson Cancer Center in Houston.  The Phase 2 trial is a two-arm, biomarker-driven study testing VAL-083 in glioblastoma multiforme (GBM) patients, who have an unmethylated promoter of the methylguanine DNA-methyltransferase (MGMT) gene.

Kintara Therapeutics reports topline results from Phase 2 clinical study of VAL-083 for recurrent GBM

The stock price of Kintara Therapeutics Inc (NASDAQ: KTRA) increased by over 25% pre-market. This is why it happened.

News for Kintara Therapeutics Stock (KTRA)